← Every company
Immunitybio Inc Executive Compensation
What Immunitybio Inc's board awarded its chief executive, and what the same award was worth once the share price had moved. Companies have had to disclose both since 2023, and they routinely differ by several times over.
IBRX on carbonthat →Latest year
2025
5 years disclosed
Awarded that year
$12.7M
Actually paid
$6.2M
after revaluation
Across every year
$57.9M
$23.7M actually paid
Year by year
Newest first. A negative figure means the award lost more than its whole value over the year.
| Year | Awarded | Actually paid |
|---|---|---|
| 20250.5×$100 → $15 | $12.7M | $6.2M |
| 20240.4×$100 → $19 | $11M | $4.1M |
| 20230.2×$100 → $38 | $1.2M | $262.4K |
| 20220.7×$100 → $38 | $4M | $2.8M |
| 20210.4×$100 → $46 | $29M | $10.4M |
Source: pay-versus-performance disclosures, read from SEC XBRL company facts. "Compensation actually paid" is a revaluation of awards that may never vest, not cash received — a board that awards shares and watches them halve discloses the second, smaller figure, and that is the disclosure working rather than a pay cut. Only the years a company tagged where the SEC's data can reach them appear here.
More on IBRX
Company overviewEverything on IBRX in one place, with the price.SEC filingsWhat IBRX's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat IBRX's own officers and directors buy and sell.Planned salesSales IBRX insiders have filed notice of.Who owns itEvery manager reporting a position in IBRX.Funds holding itWhich funds and ETFs hold IBRX, and how big a bet.LobbyingWhat IBRX spends lobbying Congress, and on what.PatentsWhat IBRX is filing at the patent office.